Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly

Increase of the Prostatic Specific Antigen (PSA) is a non-invasive, sensitive and specific markers for prostatic diseases, including prostatic cancer. However, age-related Benign Prostatic Hyperplasia (BPH), as well as prostatitis, may at the same time alter PSA values. The aim of this study was to...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2003-09, Vol.47 (3), p.207-211
Main Authors: Bo, Mario, Ventura, Manuel, Marinello, Renata, Capello, Simona, Casetta, Giovanni, Fabris, Fabrizio
Format: Article
Language:English
Subjects:
Age Factors
Aged
Aged, 80 and over
Benign Prostatic Hyperplasia (BPH)
Biological and medical sciences
Biomarkers - analysis
Diagnosis, Differential
Elderly
Gynecology. Andrology. Obstetrics
Humans
Male
Male genital diseases
Medical sciences
Middle Aged
Physical Examination
Predictive Value of Tests
Prostate - anatomy & histology
Prostate - pathology
Prostate-Specific Antigen - analysis
Prostatic Hyperplasia - diagnosis
Prostatic Neoplasms - diagnosis
Prostatic Specific Antigen (PSA)
Prostatic volume
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increase of the Prostatic Specific Antigen (PSA) is a non-invasive, sensitive and specific markers for prostatic diseases, including prostatic cancer. However, age-related Benign Prostatic Hyperplasia (BPH), as well as prostatitis, may at the same time alter PSA values. The aim of this study was to evaluate the relationship between ageing and PSA, and whether age-specific upper normal limits of PSA should be considered for elderly patients. We evaluated 569 consecutive subjects aged 60 years or more (mean age 74.2 years) who were free from malignant prostatic disease, without clinical evidence of prostatic phlogosis and who were not receiving PSA levels affecting drugs. All patients underwent Digital Rectal Examination (DRE) and Trans-Rectal Ultrasonography (TRU), with determination of the three prostatic diameters, the Maximum Adenoma Diameter (MAD) and calculation of the prostatic volume (PV) by the ellipsoid formula. PSA was determined in all patients before DRE and TRU, and the PSA free ratio was determined in those with total PSA values >4 ng/ml. The PSA density was calculated according to the formula PSA/PV. One hundred and seventy-nine subjects (31.6%) were found to have PSA values >4 ng/ml: among them, 26 (14.5%) had values exceeding 10 ng/ml. Age was slightly correlated with PV ( P
ISSN:1040-8428
1879-0461
DOI:10.1016/S1040-8428(03)00094-5